Immunome, Inc. (IMNM) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash runway ⢠High operating losses ⢠Minimal revenue IMNM has ample cash and very low leverage but is sustained by heavy R&D-driven cash burn, negligible revenue and ongoing large operating losses despite a market valuation premium.
Price Behavior
Key Price Behavior Insights: ⢠Range-bound trading ⢠Resistance capped ⢠Support holding Support Level: $19â$20 Resistance Level: $21.50â$22.30 IMNM has spent the last month in a sideways-to-slightly-down consolidation, holding support around $19â$20 but failing to clear $21.50â$22.30 after a brief peak near $23.48, signaling weak bullish momentum.
Sentiment & News
Key News Insights: ⢠Strong efficacy ⢠Large followâon ⢠Insider activity Immunome's Phase 3 varegacestat RINGSIDE data (84% reduction in progression/death; 56% ORR) drove heavy market activity and a $400M follow-on offering amid mixed insider trades as the company prepares for nearâterm corporate catalysts.
AI Summary
IMNM has moved from a speculative R&D-stage biotech to a clinical-validated, capitalized oncology developer where the investment decision should now be driven primarily by the odds and timing of varegacestat's regulatory approval and commercial executionâits recent ~$400M raise meaningfully reduces near-term liquidity risk but materially dilutes shareholders and keeps valuation event-driven.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |